BioXcel Therapeutics
BTAI
19 hedge funds and large institutions have $25M invested in BioXcel Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.19% less ownership
Funds ownership: 1.49% → 1.3% (-0.19%)
5% less funds holding
Funds holding: 20 → 19 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
27% less capital invested
Capital invested by funds: $34.2M → $25M (-$9.21M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$172K |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$152K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$124K |
| 4 |
Morgan Stanley
New York
|
+$37K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.23M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$434K |
| 3 |
Millennium Management
New York
|
-$421K |
| 4 |
PAM
Prudence Asset Management
Hong Kong
|
-$272K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$174K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$148 | +1 | New |
|
BTAI Hedge Fund Activity: Q3 2018 in Review
19 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2018, worth a combined $25M — down 27% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BTAI and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Squarepoint, opening a new position worth an estimated $172K. The largest seller was Fidelity Investments, cutting an estimated $3.23M.
- 19 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2018, down from 20 in Q2 2018.
- Funds reported $25M of BioXcel Therapeutics stock for Q3 2018, down 27% quarter-over-quarter.
- 6 funds opened new BioXcel Therapeutics positions in Q3 2018 and 7 closed out, a net change of -1 holder.
- The largest BioXcel Therapeutics buyer in Q3 2018 was Squarepoint, an estimated $172K added.
- The largest BioXcel Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $3.23M sold.
Based on aggregated 13F filings for Q3 2018.